25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

500660 (GlaxoSmithKline Pharmaceuticals Limited) Stock Analysis
Buy, Hold or Sell?

Let's analyze GlaxoSmithKline Pharmaceuticals Limited together

I guess you are interested in GlaxoSmithKline Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – GlaxoSmithKline Pharmaceuticals Limited’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – GlaxoSmithKline Pharmaceuticals Limited’s Price Targets

I'm going to help you getting a better view of GlaxoSmithKline Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.

1. Quick Overview

1.1. Quick analysis of GlaxoSmithKline Pharmaceuticals Limited (30 sec.)










1.2. What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR2.07
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR115.19
Expected worth in 1 year
INR156.19
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR217.95
Return On Investment
6.6%

For what price can you sell your share?

Current Price per Share
INR3,298.05
Expected price per share
INR3,034 - INR3,516
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)
INR3,298.05
Intrinsic Value Per Share
INR665.56 - INR871.31
Total Value Per Share
INR780.75 - INR986.49

2.2. Growth of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




Is GlaxoSmithKline Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$228.3m$207.9m$20.3m8.9%

How much money is GlaxoSmithKline Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$108.5m$69m$39.5m36.4%
Net Profit Margin24.7%17.1%--

How much money comes from the company's main activities?

2.3. Financial Health of GlaxoSmithKline Pharmaceuticals Limited (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  


Richest
#16 / 30

Most Revenue
#12 / 30
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of GlaxoSmithKline Pharmaceuticals Limited?

Welcome investor! GlaxoSmithKline Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of GlaxoSmithKline Pharmaceuticals Limited.

First you should know what it really means to hold a share of GlaxoSmithKline Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of GlaxoSmithKline Pharmaceuticals Limited is INR3,298. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of GlaxoSmithKline Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in GlaxoSmithKline Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR115.19. Based on the TTM, the Book Value Change Per Share is INR10.25 per quarter. Based on the YOY, the Book Value Change Per Share is INR2.15 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR44.24 per quarter.
Based on historical numbers we can estimate the returns while holding a share of GlaxoSmithKline Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.640.0%0.640.0%0.410.0%0.490.0%0.580.0%0.370.0%
Usd Book Value Change Per Share0.120.0%0.120.0%0.030.0%-0.160.0%0.020.0%0.150.0%
Usd Dividend Per Share0.520.0%0.520.0%0.370.0%0.650.0%0.550.0%0.410.0%
Usd Total Gains Per Share0.640.0%0.640.0%0.400.0%0.480.0%0.570.0%0.560.0%
Usd Price Per Share26.35-26.35-22.20-21.33-20.71-20.10-
Price to Earnings Ratio41.13-41.13-54.48-44.07-45.32-83.35-
Price-to-Total Gains Ratio41.33-41.33-55.62-44.65-46.72-205.46-
Price to Book Ratio19.55-19.55-18.08-16.82-16.05-15.07-
Price-to-Total Gains Ratio41.33-41.33-55.62-44.65-46.72-205.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share38.587185
Number of shares25
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.520.55
Usd Book Value Change Per Share0.120.02
Usd Total Gains Per Share0.640.57
Gains per Quarter (25 shares)15.9414.27
Gains per Year (25 shares)63.7557.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
152125455247
2104241181114104
3155361821665161
4207482462217218
5259603102769275
63117237433211332
73628443838713389
84149650244214446
946610856649716503
1051812063055318560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%6.03.00.066.7%6.03.00.066.7%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.00.0100.0%9.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of GlaxoSmithKline Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--10.25210.2520%2.147+378%-14.003+237%1.543+564%12.798-20%
Book Value Per Share--115.185115.1850%104.934+10%107.635+7%113.472+2%104.105+11%
Current Ratio--1.7901.7900%1.835-2%1.835-2%1.863-4%1.987-10%
Debt To Asset Ratio--0.5250.5250%0.500+5%0.501+5%0.490+7%0.442+19%
Debt To Equity Ratio--1.1051.1050%1.001+10%1.005+10%0.973+14%0.823+34%
Dividend Per Share--44.23644.2360%31.969+38%55.418-20%47.232-6%34.851+27%
Enterprise Value--359934688568.000359934688568.0000%303641230911.600+19%295897870482.200+22%292905277231.520+23%317779664257.411+13%
Eps--54.75554.7550%34.825+57%41.876+31%49.362+11%31.919+72%
Ev To Sales Ratio--9.6009.6000%8.792+9%8.428+14%8.775+9%9.991-4%
Free Cash Flow Per Share--74.68474.6840%32.512+130%44.394+68%42.100+77%26.299+184%
Free Cash Flow To Equity Per Share--74.68474.6840%32.512+130%14.026+432%9.471+689%-2.344+103%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--871.309----------
Intrinsic Value_10Y_min--665.564----------
Intrinsic Value_1Y_max--53.767----------
Intrinsic Value_1Y_min--48.795----------
Intrinsic Value_3Y_max--187.113----------
Intrinsic Value_3Y_min--162.982----------
Intrinsic Value_5Y_max--351.281----------
Intrinsic Value_5Y_min--294.235----------
Market Cap--381502388568.000381502388568.0000%321431008911.600+19%308787670148.867+24%299916438831.520+27%291092927431.670+31%
Net Profit Margin--0.2470.2470%0.171+45%0.202+22%0.249-1%0.178+39%
Operating Margin----0%-0%-0%-0%0.074-100%
Operating Ratio--1.0751.0750%1.143-6%1.140-6%1.199-10%1.178-9%
Pb Ratio28.633+32%19.55119.5510%18.082+8%16.821+16%16.053+22%15.067+30%
Pe Ratio60.233+32%41.12941.1290%54.484-25%44.066-7%45.315-9%83.355-51%
Price Per Share3298.050+32%2252.0002252.0000%1897.400+19%1822.767+24%1770.400+27%1718.315+31%
Price To Free Cash Flow Ratio44.160+32%30.15430.1540%58.359-48%46.424-35%45.844-34%47.712-37%
Price To Total Gains Ratio60.529+32%41.33141.3310%55.617-26%44.650-7%46.720-12%205.459-80%
Quick Ratio--1.2321.2320%1.321-7%1.722-28%1.998-38%2.035-39%
Return On Assets--0.2260.2260%0.166+36%0.192+18%0.211+7%0.152+48%
Return On Equity--0.4750.4750%0.332+43%0.386+23%0.407+17%0.281+69%
Total Gains Per Share--54.48754.4870%34.115+60%41.415+32%48.775+12%47.650+14%
Usd Book Value--228303270.000228303270.0000%207983844.900+10%213338685.300+7%224907658.560+2%231885870.840-2%
Usd Book Value Change Per Share--0.1200.1200%0.025+378%-0.164+237%0.018+564%0.150-20%
Usd Book Value Per Share--1.3481.3480%1.228+10%1.259+7%1.328+2%1.218+11%
Usd Dividend Per Share--0.5180.5180%0.374+38%0.648-20%0.553-6%0.408+27%
Usd Enterprise Value--4211235856.2464211235856.2460%3552602401.666+19%3462005084.642+22%3426991743.609+23%3718022071.812+13%
Usd Eps--0.6410.6410%0.407+57%0.490+31%0.578+11%0.373+72%
Usd Free Cash Flow--148027230.000148027230.0000%64441260.000+130%87990240.000+68%83443623.120+77%45819817.290+223%
Usd Free Cash Flow Per Share--0.8740.8740%0.380+130%0.519+68%0.493+77%0.308+184%
Usd Free Cash Flow To Equity Per Share--0.8740.8740%0.380+130%0.164+432%0.111+689%-0.027+103%
Usd Market Cap--4463577946.2464463577946.2460%3760742804.266+19%3612815740.742+24%3509022334.329+27%3405787250.951+31%
Usd Price Per Share38.587+32%26.34826.3480%22.200+19%21.326+24%20.714+27%20.104+31%
Usd Profit--108526860.000108526860.0000%69025320.000+57%83000845.200+31%97837585.560+11%67665410.280+60%
Usd Revenue--438657570.000438657570.0000%404084070.000+9%407731077.000+8%389803609.260+13%371408555.700+18%
Usd Total Gains Per Share--0.6380.6380%0.399+60%0.485+32%0.571+12%0.558+14%
 EOD+2 -4MRQTTM+0 -0YOY+30 -73Y+28 -95Y+27 -1010Y+26 -12

3.3 Fundamental Score

Let's check the fundamental score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1560.233
Price to Book Ratio (EOD)Between0-128.633
Net Profit Margin (MRQ)Greater than00.247
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.232
Current Ratio (MRQ)Greater than11.790
Debt to Asset Ratio (MRQ)Less than10.525
Debt to Equity Ratio (MRQ)Less than11.105
Return on Equity (MRQ)Greater than0.150.475
Return on Assets (MRQ)Greater than0.050.226
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.500
Ma 20Greater thanMa 503,321.793
Ma 50Greater thanMa 1003,086.483
Ma 100Greater thanMa 2002,826.033
OpenGreater thanClose3,375.000
Total5/5 (100.0%)

4. In-depth Analysis

4.1 About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, manufactures, and distributes pharmaceutical products and vaccines worldwide. It offers prescription and non-prescription drugs for asthma, infectious diseases, mental health, digestive conditions, and other diseases; and vaccines for various therapeutic areas, primarily cancer. The company also provides medicinal substances, such as antibiotics, endocrine products, and basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, and its salts and esters; glycosides and vegetable alkaloids; and chemically pure sugar. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was founded in 1924 and is headquartered in Mumbai, India.

Fundamental data was last updated by Penke on 2025-06-24 19:20:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ GlaxoSmithKline Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • A Net Profit Margin of 24.7%Β means thatΒ ₹0.25 for each ₹1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 24.7%. The company is making a huge profit. +2
  • The TTM is 24.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ24.7%TTM24.7%0.0%
TTM24.7%YOY17.1%+7.7%
TTM24.7%5Y24.9%-0.2%
5Y24.9%10Y17.8%+7.1%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ24.7%11.4%+13.3%
TTM24.7%10.2%+14.5%
YOY17.1%10.5%+6.6%
3Y20.2%9.4%+10.8%
5Y24.9%12.7%+12.2%
10Y17.8%11.6%+6.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ GlaxoSmithKline Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • 22.6% Return on Assets means thatΒ GlaxoSmithKline Pharmaceuticals Limited generatedΒ ₹0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 22.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 22.6%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ22.6%TTM22.6%0.0%
TTM22.6%YOY16.6%+6.0%
TTM22.6%5Y21.1%+1.5%
5Y21.1%10Y15.2%+5.9%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ22.6%4.9%+17.7%
TTM22.6%4.9%+17.7%
YOY16.6%4.4%+12.2%
3Y19.2%5.2%+14.0%
5Y21.1%4.5%+16.6%
10Y15.2%4.6%+10.6%
4.3.1.3. Return on Equity

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • 47.5% Return on Equity means GlaxoSmithKline Pharmaceuticals Limited generated ₹0.48Β for eachΒ ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 47.5%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 47.5%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ47.5%TTM47.5%0.0%
TTM47.5%YOY33.2%+14.3%
TTM47.5%5Y40.7%+6.8%
5Y40.7%10Y28.1%+12.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ47.5%9.6%+37.9%
TTM47.5%9.6%+37.9%
YOY33.2%7.0%+26.2%
3Y38.6%7.6%+31.0%
5Y40.7%7.6%+33.1%
10Y28.1%8.7%+19.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of GlaxoSmithKline Pharmaceuticals Limited.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient GlaxoSmithKline Pharmaceuticals Limited is operatingΒ .

  • Measures how much profit GlaxoSmithKline Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • An Operating Margin of 0.0%Β means the company generated ₹0.00 Β for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y7.4%-7.4%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
TTM-9.6%-9.6%
YOY-8.1%-8.1%
3Y-4.2%-4.2%
5Y-9.0%-9.0%
10Y7.4%10.4%-3.0%
4.3.2.2. Operating Ratio

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Pharmaceuticals industry mean).
  • An Operation Ratio of 1.07 means that the operating costs are ₹1.07 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.075. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.075. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.075TTM1.0750.000
TTM1.075YOY1.143-0.069
TTM1.0755Y1.199-0.125
5Y1.19910Y1.178+0.021
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0751.231-0.156
TTM1.0751.176-0.101
YOY1.1431.220-0.077
3Y1.1401.233-0.093
5Y1.1991.226-0.027
10Y1.1781.211-0.033
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of GlaxoSmithKline Pharmaceuticals Limited.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Pharmaceuticals industry mean).
  • A Current Ratio of 1.79Β means the company has ₹1.79 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.790. The company is able to pay all its short-term debts. +1
  • The TTM is 1.790. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.790TTM1.7900.000
TTM1.790YOY1.835-0.045
TTM1.7905Y1.863-0.073
5Y1.86310Y1.987-0.124
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7901.933-0.143
TTM1.7901.986-0.196
YOY1.8352.234-0.399
3Y1.8352.088-0.253
5Y1.8632.256-0.393
10Y1.9872.036-0.049
4.4.3.2. Quick Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • A Quick Ratio of 1.23Β means the company can pay off ₹1.23 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.232. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.232. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.232TTM1.2320.000
TTM1.232YOY1.321-0.090
TTM1.2325Y1.998-0.767
5Y1.99810Y2.035-0.037
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2321.059+0.173
TTM1.2321.109+0.123
YOY1.3211.245+0.076
3Y1.7221.424+0.298
5Y1.9981.642+0.356
10Y2.0351.573+0.462
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of GlaxoSmithKline Pharmaceuticals Limited.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of GlaxoSmithKline Pharmaceuticals LimitedΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ GlaxoSmithKline Pharmaceuticals Limited to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.53Β means that GlaxoSmithKline Pharmaceuticals Limited assets areΒ financed with 52.5% credit (debt) and the remaining percentage (100% - 52.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.525. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.525. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.525TTM0.5250.000
TTM0.525YOY0.500+0.025
TTM0.5255Y0.490+0.035
5Y0.49010Y0.442+0.048
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5250.324+0.201
TTM0.5250.326+0.199
YOY0.5000.336+0.164
3Y0.5010.314+0.187
5Y0.4900.328+0.162
10Y0.4420.338+0.104
4.5.4.2. Debt to Equity Ratio

Measures ifΒ GlaxoSmithKline Pharmaceuticals Limited is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 110.5% means that company has ₹1.11 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.105. The company is able to pay all its debts with equity. +1
  • The TTM is 1.105. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.105TTM1.1050.000
TTM1.105YOY1.001+0.105
TTM1.1055Y0.973+0.133
5Y0.97310Y0.823+0.150
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1050.492+0.613
TTM1.1050.492+0.613
YOY1.0010.547+0.454
3Y1.0050.488+0.517
5Y0.9730.502+0.471
10Y0.8230.528+0.295
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every ₹1 in earnings GlaxoSmithKline Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced butΒ always compareΒ GlaxoSmithKline Pharmaceuticals Limited to theΒ Pharmaceuticals industry mean.
  • A PE ratio of 41.13 means the investor is paying ₹41.13Β for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 60.233. Based on the earnings, the company is expensive. -2
  • The MRQ is 41.129. Based on the earnings, the company is overpriced. -1
  • The TTM is 41.129. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD60.233MRQ41.129+19.104
MRQ41.129TTM41.1290.000
TTM41.129YOY54.484-13.355
TTM41.1295Y45.315-4.186
5Y45.31510Y83.355-38.040
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD60.23328.505+31.728
MRQ41.12925.404+15.725
TTM41.12927.574+13.555
YOY54.48422.687+31.797
3Y44.06623.741+20.325
5Y45.31528.695+16.620
10Y83.35528.267+55.088
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 44.160. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 30.154. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 30.154. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD44.160MRQ30.154+14.006
MRQ30.154TTM30.1540.000
TTM30.154YOY58.359-28.205
TTM30.1545Y45.844-15.691
5Y45.84410Y47.712-1.868
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD44.16025.213+18.947
MRQ30.15422.139+8.015
TTM30.15417.570+12.584
YOY58.35927.354+31.005
3Y46.42436.662+9.762
5Y45.84436.120+9.724
10Y47.71230.424+17.288
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ GlaxoSmithKline Pharmaceuticals Limited is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 19.55 means the investor is paying ₹19.55Β for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 28.633. Based on the equity, the company is expensive. -2
  • The MRQ is 19.551. Based on the equity, the company is expensive. -2
  • The TTM is 19.551. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD28.633MRQ19.551+9.081
MRQ19.551TTM19.5510.000
TTM19.551YOY18.082+1.469
TTM19.5515Y16.053+3.498
5Y16.05310Y15.067+0.986
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD28.6333.941+24.692
MRQ19.5514.187+15.364
TTM19.5514.216+15.335
YOY18.0823.209+14.873
3Y16.8213.242+13.579
5Y16.0533.625+12.428
10Y15.0673.591+11.476
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in INR. All numbers in thousands.

Summary
Total Assets41,080,800
Total Liabilities21,567,700
Total Stockholder Equity19,513,100
 As reported
Total Liabilities 21,567,700
Total Stockholder Equity+ 19,513,100
Total Assets = 41,080,800

Assets

Total Assets41,080,800
Total Current Assets34,098,900
Long-term Assets6,981,900
Total Current Assets
Cash And Cash Equivalents 5,388,500
Short-term Investments 20,537,000
Net Receivables 2,925,500
Inventory 4,817,400
Other Current Assets 430,500
Total Current Assets  (as reported)34,098,900
Total Current Assets  (calculated)34,098,900
+/-0
Long-term Assets
Property Plant Equipment 2,838,600
Long-term Assets Other 518,500
Long-term Assets  (as reported)6,981,900
Long-term Assets  (calculated)3,357,100
+/- 3,624,800

Liabilities & Shareholders' Equity

Total Current Liabilities19,051,700
Long-term Liabilities2,516,000
Total Stockholder Equity19,513,100
Total Current Liabilities
Accounts payable 7,082,600
Other Current Liabilities 715,000
Total Current Liabilities  (as reported)19,051,700
Total Current Liabilities  (calculated)7,797,600
+/- 11,254,100
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt99,500
Long-term Liabilities  (as reported)2,516,000
Long-term Liabilities  (calculated)99,500
+/- 2,416,500
Total Stockholder Equity
Total Stockholder Equity (as reported)19,513,100
Total Stockholder Equity (calculated)0
+/- 19,513,100
Other
Capital Stock1,694,100
Common Stock Shares Outstanding 169,406
Net Invested Capital 19,513,100
Net Working Capital 15,047,200
Property Plant and Equipment Gross 2,838,600



6.2. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
30,548,849
30,038,353
39,474,827
39,113,109
31,355,410
31,146,474
46,332,778
33,265,848
35,566,175
41,080,800
41,080,80035,566,17533,265,84846,332,77831,146,47431,355,41039,113,10939,474,82730,038,35330,548,849
   > Total Current Assets 
21,737,270
16,742,459
21,864,082
20,094,620
17,748,814
22,026,398
37,080,323
24,942,645
27,984,186
34,098,900
34,098,90027,984,18624,942,64537,080,32322,026,39817,748,81420,094,62021,864,08216,742,45921,737,270
       Cash And Cash Equivalents 
562,336
1,068,622
1,100,100
300,300
60,000
2,061,192
561,271
349,009
641,712
5,388,500
5,388,500641,712349,009561,2712,061,19260,000300,3001,100,1001,068,622562,336
       Short-term Investments 
0
7,672,460
10,690,145
10,490,145
9,570,145
7,320,000
25,446,923
16,191,788
17,926,520
20,537,000
20,537,00017,926,52016,191,78825,446,9237,320,0009,570,14510,490,14510,690,1457,672,4600
       Net Receivables 
1,265,650
1,707,967
1,469,589
1,204,873
998,012
2,156,046
2,052,389
1,923,750
2,220,571
2,925,500
2,925,5002,220,5711,923,7502,052,3892,156,046998,0121,204,8731,469,5891,707,9671,265,650
       Inventory 
5,258,666
4,257,974
5,001,833
4,864,935
4,830,322
5,466,981
5,346,954
4,599,704
5,250,482
4,817,400
4,817,4005,250,4824,599,7045,346,9545,466,9814,830,3224,864,9355,001,8334,257,9745,258,666
       Other Current Assets 
882,363
894,389
1,639,395
352,065
276,371
2,066,161
233,666
232,855
20,298
430,500
430,50020,298232,855233,6662,066,161276,371352,0651,639,395894,389882,363
   > Long-term Assets 
0
13,312,189
17,660,119
19,051,760
13,606,596
9,107,000
9,252,247
8,323,200
7,581,989
6,981,900
6,981,9007,581,9898,323,2009,252,2479,107,00013,606,59619,051,76017,660,11913,312,1890
       Property Plant Equipment 
4,717,116
8,259,263
11,730,238
13,670,968
8,270,867
3,541,241
3,254,472
3,151,200
3,107,318
2,838,600
2,838,6003,107,3183,151,2003,254,4723,541,2418,270,86713,670,96811,730,2388,259,2634,717,116
       Intangible Assets 
0
322,473
726,818
655,400
496,251
433,640
344,974
340,908
235,538
0
0235,538340,908344,974433,640496,251655,400726,818322,4730
       Long-term Assets Other 
0
306,098
408,414
322,761
149,203
501,700
13,318
524,300
6,060
518,500
518,5006,060524,30013,318501,700149,203322,761408,414306,0980
> Total Liabilities 
8,716,369
9,969,795
18,901,538
17,714,817
13,149,361
16,363,875
19,703,220
15,853,118
17,789,778
21,567,700
21,567,70017,789,77815,853,11819,703,22016,363,87513,149,36117,714,81718,901,5389,969,7958,716,369
   > Total Current Liabilities 
5,792,107
7,202,325
15,998,637
14,543,195
10,242,572
13,545,807
16,984,288
13,263,701
15,249,461
19,051,700
19,051,70015,249,46113,263,70116,984,28813,545,80710,242,57214,543,19515,998,6377,202,3255,792,107
       Short-term Debt 
0
0
0
0
0
240
0
0
0
0
000024000000
       Short Long Term Debt 
0
6,060
4,060
4,060
1,530
240
0
0
0
0
00002401,5304,0604,0606,0600
       Accounts payable 
0
5,224,802
6,462,468
4,825,341
3,575,851
4,644,700
5,705,487
4,277,900
6,254,097
7,082,600
7,082,6006,254,0974,277,9005,705,4874,644,7003,575,8514,825,3416,462,4685,224,8020
       Other Current Liabilities 
0
312,952
199,157
150,647
651,258
2,638,500
1,292
562,000
17,727
715,000
715,00017,727562,0001,2922,638,500651,258150,647199,157312,9520
   > Long-term Liabilities 
0
2,767,470
2,902,901
3,171,622
2,906,789
2,818,100
2,718,932
2,589,400
2,540,317
2,516,000
2,516,0002,540,3172,589,4002,718,9322,818,1002,906,7893,171,6222,902,9012,767,4700
       Long term Debt Total 
15,950
9,890
5,830
1,770
268,612
202,499
76,235
34,554
0
0
0034,55476,235202,499268,6121,7705,8309,89015,950
> Total Stockholder Equity
21,832,480
20,068,558
20,573,289
21,398,292
18,206,049
14,782,599
26,629,558
17,412,730
17,776,397
19,513,100
19,513,10017,776,39717,412,73026,629,55814,782,59918,206,04921,398,29220,573,28920,068,55821,832,480
   Common Stock
847,030
847,030
847,030
1,694,060
1,694,060
1,694,060
1,694,060
1,694,060
0
0
001,694,0601,694,0601,694,0601,694,0601,694,060847,030847,030847,030
   Retained Earnings 
20,985,450
19,221,528
19,726,259
19,704,232
16,511,989
13,088,539
24,935,498
15,718,670
8,551,862
0
08,551,86215,718,67024,935,49813,088,53916,511,98919,704,23219,726,25919,221,52820,985,450
   Capital Surplus 0000000000
   Treasury Stock0000000000
   Other Stockholders Equity 0000000000



6.3. Balance Sheets

Currency in INR. All numbers in thousands.




6.4. Cash Flows

Currency in INR. All numbers in thousands.




6.5. Income Statements

Currency in INR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue37,492,100
Cost of Revenue-13,908,600
Gross Profit23,583,50023,583,500
 
Operating Income (+$)
Gross Profit23,583,500
Operating Expense-26,386,400
Operating Income11,105,700-2,802,900
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense26,386,4000
 
Net Interest Income (+$)
Interest Income0
Interest Expense-13,100
Other Finance Cost-0
Net Interest Income-13,100
 
Pretax Income (+$)
Operating Income11,105,700
Net Interest Income-13,100
Other Non-Operating Income Expenses0
Income Before Tax (EBT)12,598,80011,105,700
EBIT - interestExpense = -13,100
9,275,800
9,288,900
Interest Expense13,100
Earnings Before Interest and Taxes (EBIT)012,611,900
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax12,598,800
Tax Provision-3,323,000
Net Income From Continuing Ops9,275,8009,275,800
Net Income9,275,800
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net013,100
 

Technical Analysis of GlaxoSmithKline Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of GlaxoSmithKline Pharmaceuticals Limited. The general trend of GlaxoSmithKline Pharmaceuticals Limited is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine GlaxoSmithKline Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. GlaxoSmithKline Pharmaceuticals Limited Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlaxoSmithKline Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3,516.

The bearish price targets are: 3,152 > 3,107 > 3,034.

Know someone who trades $500660? Share this with them.πŸ‘‡

GlaxoSmithKline Pharmaceuticals Limited Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlaxoSmithKline Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlaxoSmithKline Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlaxoSmithKline Pharmaceuticals Limited. The current macd is 61.35.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for GlaxoSmithKline Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the GlaxoSmithKline Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlaxoSmithKline Pharmaceuticals Limited. The current adx is 29.40.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy GlaxoSmithKline Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
GlaxoSmithKline Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlaxoSmithKline Pharmaceuticals Limited. The current sar is 3,173.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlaxoSmithKline Pharmaceuticals Limited. The current rsi is 53.50. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlaxoSmithKline Pharmaceuticals Limited. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the GlaxoSmithKline Pharmaceuticals Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
GlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator ChartGlaxoSmithKline Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlaxoSmithKline Pharmaceuticals Limited. The current cci is -10.86277513.

GlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlaxoSmithKline Pharmaceuticals Limited. The current cmo is 1.21415097.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlaxoSmithKline Pharmaceuticals Limited. The current willr is -58.03994827.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that GlaxoSmithKline Pharmaceuticals Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GlaxoSmithKline Pharmaceuticals Limited Daily Williams %R ChartGlaxoSmithKline Pharmaceuticals Limited Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlaxoSmithKline Pharmaceuticals Limited. The current atr is 113.03.

GlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlaxoSmithKline Pharmaceuticals Limited. The current obv is 1,241,020.

GlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartGlaxoSmithKline Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlaxoSmithKline Pharmaceuticals Limited. The current mfi is 37.76.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
GlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartGlaxoSmithKline Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlaxoSmithKline Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-22MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

GlaxoSmithKline Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.500
Ma 20Greater thanMa 503,321.793
Ma 50Greater thanMa 1003,086.483
Ma 100Greater thanMa 2002,826.033
OpenGreater thanClose3,375.000
Total5/5 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of GlaxoSmithKline Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on GlaxoSmithKline Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlaxoSmithKline Pharmaceuticals Limited

I send you an email if I find something interesting about GlaxoSmithKline Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about GlaxoSmithKline Pharmaceuticals Limited.

Receive notifications about GlaxoSmithKline Pharmaceuticals Limited in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.